Key Takeaways
- Volume-led growth, margin stuck: Consolidated revenue rose 13% YoY on ~10-12% volume growth, but EBITDA margin compressed to 11.8% as investments, labor-code costs and a still-ramping Ethoxylation plant weighed on profitability.
- The Ethylene Oxide bottleneck has a clock: The new 15,000 MTPA facility is ramping steadily, but EO supply is the binding constraint; management expects that to ease during calendar 2026, with full utilization targeted by around 2027.
- KSA is the big strategic bet: The Board approved a greenfield facility in Saudi Arabia, a move management says was planned well before tariffs and is backed by raw-material economics and at least two customer understandings, though capex details are still pending.
- B2C is the margin swing factor: The consumer business remains a drag; management is actively reassessing it and flagged that exiting or selling parts could release ~₹150 crore and mechanically lift margins back toward 15%.
- What to watch next quarter: Whether the balance Ethoxylation capacity comes onstream as promised, any concrete decision on the B2C vertical, and the first capex quantification for the KSA project.
The Ethoxylation Ramp & the EO Constraint
- New capacity online, but throttled: The 15,000 MTPA facility at Unitop has been capitalized and is in steady ramp-up, yet near-term output is constrained by Ethylene Oxide availability. Management is managing supplies prudently and using reactor fungibility to push non-EO product lines in the meantime.
- Two-phase unlock: The first phase is already ramping; the balance second phase is expected onstream in Q4 FY26. Optimal utilization, potentially reaching 90%, is guided for end of FY27, roughly two years out.
- Margin implication: Until EO supply eases, the new capacity cannot fully convert into operating leverage. Management expects margins to stay in the 12-13% range for the balance of this year and next, barring a B2C divestment.
Menezes: "Availability of Ethylene Oxide continues to be a near-term constraint. However, we are managing supplies prudently and are encouraged by indications that the situation should ease during the course of this calendar year."
KSA Greenfield: Rationale, Timing & Open Questions
- The project: Board granted in-principle approval for a greenfield specialty chemicals manufacturing facility in Saudi Arabia under a wholly owned subsidiary, Rossari International Limited Company. The company was already formed and disclosed a few quarters back.
- Stated rationale: Management cited raw material availability and pricing advantage, technology familiarity, and strong regional demand. It pushed back on the idea that the move is tariff-driven, noting the strategy has been in planning for almost a year.
- Customer groundwork: Management disclosed an understanding with at least two customers for product supply; formal agreements and documentation will follow as the project advances.
- What is still unknown: The final project cost, land details, and capex amount are not yet determined. The initial $8 million equity infusion approval is for evaluation work only; management confirmed the eventual capex will be substantially higher. Two senior project professionals based in KSA have been identified to join once the project is greenlit.
- Bandwidth concern unaddressed: When asked whether KSA expansion stretches management bandwidth after heavy India capex, management reiterated that India remains the topmost priority but did not directly engage with the bandwidth question.
B2C: The Drag That Could Flip
- Subdued performance, moderating losses: The institutional and B2C business remained subdued in Q3, though losses continued to moderate on improved product mix, operational efficiency, and cost discipline. The company is evaluating non-profitable products in the portfolio.
- Active reassessment: Management is re-looking at the entire B2C vertical to reduce losses and may take a decision in the next few quarters on what to do with it. The business currently requires money, investment, cash burn, marketing promotions and free sampling, none of which are being funded at scale.
- The margin math: Selling part of the consumer businesses is expected to bring in ~₹150 crore and, by removing the cash drag, would automatically lift profits back toward 15%, per management's framing.
Sablok: "We are re-looking at that business all over again to reduce losses. And on a longer-term basis, also, we are assessing this piece of business of ours, and maybe in the next few quarters we may take some decisions on how we really plan to or what we plan to do with this B2C vertical."
Segment & Export Performance
| Segment | Trend | Commentary |
|---|---|---|
| HPPC | ▲ 11% YoY | Stable demand amid a muted domestic environment; Europe export sentiment soft but compensated by MENA, Middle East and Turkey. |
| Textile Specialty Chemicals | ▲ 18% YoY | Export-driven growth from new customers in Turkey, Uzbekistan, Morocco, Philippines, Indonesia. Domestic soft as large end-customers like Welspun and Indo Count were hit by tariffs, though Surat and Ludhiana saw some demand recovery. |
| Animal Health & Nutrition | ▲ 39% YoY | Strong quarter with improved traction across key end-user markets. Export initiative gaining ground with new country additions: Nepal, Bangladesh, Egypt, Nigeria, Thailand, and select South American markets. Second half is seasonally better. |
| Institutional & B2C | ▼ Subdued | Losses moderating but performance still weak; active reassessment underway. |
- Export trajectory: International business grew 26% in 9M FY26, driven by deeper relationships, customer base expansion and increased wallet share with strategic partners. Management expects exports to keep growing, though perhaps not at the current rate.
- Volume is the whole story: Per an analyst's math, consolidated revenue growth was entirely volume-driven at close to 10-12%, with price movements across products largely netting out. Segment-level bifurcation was not provided.
New Product Pipeline & R&D
- R&D capability build: Senior people have been brought into the R&D function in the last six months. New product developments are expected to start playing out in the near future.
- Bio-surfactants milestone: The "best personal care company in the world" plus two large multinationals have approved Rossari's bio-surfactants, a validation that management highlighted as a significant breakthrough.
- Fermentation and bio-surfactants economics: New plants for fermentation and bio-surfactants are expected to deliver a much better EBITDA percentage in the coming financial year, alongside absolute growth.
- New product contribution: Sales from new products now exceed 20% of revenue.
Chari: "In fact, today, we have news that the best personal care company in the world has approved our bio-surfactants. 2 big multinationals of..."
Capex Cycle: Heavy Lifting Done, Optimization Ahead
- Capacity capex largely complete: Management stated that most capacity enhancement capex is done. The focus for the next 2-3 years shifts to optimally utilizing existing capacities, filling up plants in India, and bringing in newer products.
- Remaining capex is product-development led: Non-EO based capex at Unitop, Tristar and Rossari will be phased through the next year, skewed toward the second half (Q3 and Q4), and directed at product development and piloting rather than capacity expansion.
- Overseas capacity additions: A small formulation facility in Thailand is expected upstream by end of Q4 FY26 or early Q1 FY27, starting with textile formulations and later adding AHN and HPPC products. A new trace mineral and vitamin premix plant in Bangladesh is ready to start in the current quarter.
- Financial metrics under pressure: Profitability has been flat at ~₹30 crore PAT for three years with ROCE below 15%. Management pointed to B2C reassessment and capacity additions as the path to improvement but did not provide specific targets or a timeline for ROCE recovery.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ethoxylation capacity | Balance second phase onstream; full utilization ~90% targeted | Q4 FY26 for phase 2; end of FY27 for optimal utilization |
| Ethylene Oxide supply | Situation expected to ease | During calendar 2026 |
| Margin range | 12-13% EBITDA, barring B2C action | Balance of FY26 and through next year until EO eases by Q3 |
| B2C vertical decision | Reassessment may lead to a decision on the vertical's future | Next few quarters |
| Thailand formulation facility | Small facility upstream for textile, later AHN and HPPC | End of Q4 FY26 or early Q1 FY27 |
| Bangladesh AHN plant | New trace mineral and vitamin premix plant ready to start | Current quarter (Q4 FY26) |
| KSA project capex detail | Detailed capex quantification after assessment and evaluation | No date; formal Board approval for capex amount to follow |
| Non-EO capex (Unitop, Tristar, Rossari) | Phased product-development capex | Q3 and Q4 of next year (FY27) |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹581.7 cr, +13% YoY |
| Consolidated EBITDA | ₹68.9 cr, margin 11.8% |
| Core B2B EBITDA margin | ~14%, marginally lower than normalized band of 15%-16% |
| PAT | ~₹30 cr per quarter, broadly flat over several quarters (per an analyst's math) |
| ROCE | sub-15%, close to 13% (per an analyst's math) |
| HPPC segment growth | +11% YoY |
| Textile Specialty Chemicals segment growth | +18% YoY |
| Animal Health and Nutrition segment growth | +39% YoY |
| Export contribution | 33% of total turnover, 9M FY26 exports +26% YoY |
| Domestic growth (9M FY26) | +10% YoY |
| Volume growth (consolidated YoY) | ~10%-12%, entire growth attributed to volume |
| New product sales share | 20%-plus of total sales |
| Unitop new Ethoxylation facility utilization | 10%-15% currently, expected to reach up to 90% by end of FY27 |
| Total capex capitalized by end of FY26 | ~₹200 cr across the group |
| Expected proceeds from sale of part of consumer businesses | ~₹150 cr |